Pemvidutide Promise | Explore pemvidutide's potential in MASH and obesity treatment, with unprecedented liver fat reduction and significant weight loss results |
Expanding Horizons | Delve into Altimmune's strategic expansion of pemvidutide applications to include alcohol use disorder and alcoholic liver disease |
Clinical Milestones | Anticipate key clinical trial outcomes, including the Phase 2b IMPACT trial for MASH, with top-line data expected in Q2 2025 |
Market Potential | Analyst price targets range from $12 to $28, with projected peak U.S. sales exceeding $2.5 billion for MASH indication alone |
Metrics to compare | ALT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.5x | −3.5x | −0.4x | |
PEG Ratio | −0.24 | −0.03 | 0.00 | |
Price/Book | 2.1x | 1.4x | 2.6x | |
Price / LTM Sales | 16,422.3x | 99.0x | 3.0x | |
Upside (Analyst Target) | - | 301.1% | 53.6% | |
Fair Value Upside | Unlock | 4.9% | 7.6% | Unlock |
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.